The financing includes funding from several angel networks including Bellingham Angels, Alliance of Angels, Keiretsu, Tacoma Angel Network and Zino Society.
Robert Brown, CEO of Healionics, said: “This financing reflects the great progress Healionics has made over the past year, including doubling the number of research agreements for our Star biomaterial and consistently achieving corporate milestones such as scaling up manufacturing processes, accelerating preclinical studies and advancing business development activities.
“We are pleased to receive such support in this current economic climate. These funds will enable the company to continue to make significant progress in achieving key milestones, including additional preclinical studies and development of a degradable form of Star material that will provide further evidence of the efficacy and versatility of Star biomaterial.”